Fig. 3.

The effects of EA and the DRD1 agonist SKF38393 on anxiety-like behaviors induced by microinjection of the DRD1 antagonist SCH23390 in the BLA. A Schematic of EA treatment and drug injection and behavioral testing. B Diagram showing the cannulation location (left) and a representative image showing a coronal section with the cannula tip in the BLA from the injection of a mouse brain (right). C The effect of treatment in each group on the PWTs. (n = 8–9 per group). D–F The effect of treatment in each group on anxiety-like behaviors in the EPM (D) and OFT (E–F). (n = 7–9 per group). G Representative diagram showing tracked movement and activity heatmaps in the EPM. H Representative diagram showing tracked movement and activity heatmaps in the OFT. Data are expressed as the mean ± SEM. Tukey’s post hoc test: *p < 0.05 comparison of the two groups